小鵬汽車(XPEV.US)新技術料降研發成本 美股升逾一成
小鵬汽車(XPEV.US)於「小鵬汽車2023技術架構」發布會上發布SEPA 2.0(扶搖)架構。小鵬汽車董事長何小鵬透露,目前公司內部有10款車型正在研發,基於扶搖框架,新車研發周期將縮短20%,零部件通用化率提升至80%,整車綜合研發成本降低50%。
受消息刺激,小鵬汽車美股顯著上升,最新升13.7%,報11.28美元;另外兩間美股上市的中國電動車製造商股價同樣向上,蔚來(NIO.US)最新升5.6%至9.77美元,理想汽車(LI.US)升4.3%至25.62美元。(ek/m)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.